Versum Investor Wants 'Overly Restrictive' Poison Pill Axed
A Versum Materials investor blasted the adoption of an "overly restrictive" poison pill after Merck KGaA's $6 billion challenge to the company's planned Entegris merger, contending in a Delaware Chancery suit Friday...To view the full article, register now.
Already a subscriber? Click here to view full article